| Literature DB >> 22558298 |
Kangmin Duan1, William M McCullough, Michael G Surette, Tony Ware, Jiuzhou Song.
Abstract
To explore gene-environment interactions, based on temporal gene expression information, we analyzed gene and treatment information intensively and inferred interaction networks accordingly. The main idea is that gene expression reflects the response of genes to environmental factors, assuming that variations of gene expression occur under different conditions. Then we classified experimental conditions into several subgroups based on the similarity of temporal gene expression profiles. This procedure is useful because it allows us to combine diverse gene expression data as they become available, and, especially, allowing us to lay the regulatory relationships on a concrete biological basis. By estimating the activation points, we can visualize the gene behavior, and obtain a consensus gene activation order, and hence describe conditional regulatory relationships. The estimation of activation points and building of synthetic genetic networks may result in important new insights in the ongoing endeavor to understand the complex network of gene regulation.Entities:
Mesh:
Year: 2012 PMID: 22558298 PMCID: PMC3338772 DOI: 10.1371/journal.pone.0035993
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Expression Profiles of the 31 Genes in One Condition.
Figure 2The aprA gene expression profiles in 72 conditions and 60 time points.
Figure 3The fluctuation of standard deviation of aprA gene in different conditions and time series.
Figure 4The networks of the five subgroups.
The thickness and color of line indicate the popularity in each comprehensive genetic network. The direction of transit is clockwise.
Figure 5Pattern matching of temporal data.
A. This is an original similarity matrix from PCA similarity analysis, the deep red on diagonal is similarity of itself, the similarity is 1. B. This is the reorganized similarity matrix based on clustering analysis.
Figure 6The mapping of unknown condition based on pattern matching of expression.
For example, the expression pattern in the complex media of sputum extracts looks most like minimal media growth conditions. The clustering analysis of the expression data for the 72 conditions can yield groups of conditions with similar expression profiles, which can be used for pattern mapping of unknown condition based on expression pattern mapping.
Figure 7The expression profile of the rpoS gene.
The turn point is the half position from lift maximum, the turn off point is the half position from the right maximum.
Figure 8The visualization tool with Visual Basic.
The red bar indicates the gene turning off point, the green bar indicates the gene turning on point. The gene order by genes and conditions can obtained via sorting the data with turn on and turn off options.
The Gene Activation Order in the Networks.
| Network | Status | Activation Order (from left to right) |
| A | Turn-on | algD, adh, znuA, xcpR/toxA, pKD201/pKD202/pMS404, rhlA, D203, fliC, exoS, exoT |
| Turn-off | RpoS, xcpR, migA, znuA, xcpR, pKD201/pKD202/pKD203, rhlA, rhlR, plcH, pMS404, phzA1/phzA2 | |
| B | Turn-on | pKD201, pKD203/pKD202, znuA, rpoS/rnr, xcpR, exoS, phzA1/phzA2, |
| Turn-off | phzA1/xcpR, pKD201/pKD202/pKD203, rpoS/rnr, phzA1/phzA2, hemo, exoY, exoS. | |
| C | Turn-on | Adh/aprA, exoY, toxA/xcpR/rpoS, pKD201/pKD202/pKD203, plcH, pilG, phzA1/phzA2, lasR, znuA, rnr |
| Turn-off | plcH, rhlA/rhlR/toxA, pKD202/pKD201, exoS/lasR, rpoS, algD, phzA1/PhzA2, migA, pMS404, znuA, aprA, pKD203, | |
| D | Turn-on | pKD202, pKD201, znuA, pKD203, |
| Turn-off | PlcH, rpoS, pKD201, pKD202, pKD203, rnr, xcpR, toxA, algD, lasA, pilT | |
| E | Turn-on | pMS404, rhlR, toxA |
| Turn-off | pMS404, znuA, lasR, phzA1 |
The list of the gene reporters used in this study.
| Gene | Function | PA number |
| lasI (pKD201) | AHL synthase | PA1432 |
| lasR | AHL dependent transcriptional regulator | PA1430 |
| rhlI (pKD202) | AHL synthase (rhlL) | PA3476 |
| rhlR | AHL dependent transcriptional regulator | PA3477 |
| lasA | protease (staphylolytic protease preproenzyme LasA) | PA1871 |
| lasB (pMS404) | Elastase | PA3724 |
| aprA | alkaline protease (alkaline metalloproteinase precursor) | PA1249 |
| xcpP | xcp secretion pathway (differient orientation from xcpR) | PA3104 |
| xcpR | xcp (general secretion pathway protein E) | PA3103 |
| rhlA | rhaminolipid (rhamnosyltransferase chain A) | PA3479 |
| rpoS | stationary phase sigma | PA3622 |
| gacA | transcriptional activator,response regulator | PA2586 |
| pilT | Type IV pili (twitching motility protein PilT, pilT I followed by pilU) | PA0395 |
| pilG | Type IV fimbrial (Part of the pilGHIJKL gene cluster) | PA0408 |
| algD | alginate (GDP-mannose 6-dehydrogenase AlgD), first of 18-kb alginate operon. | PA3540 |
| plcH | hemolytic phopholipaseC (hemolysin) precursor | PA0844 |
| toxA | exotoxinA | PA1148 |
| exoS | exoenzymeS (ADP-ribosyltransferase) | PA3841 |
| exoT | exoenzymeT (99% similar to ADP-ribosyltransferase (exoenzyme 53)) | PA0044 |
| exoY | adenylate cyclase | PA2191 |
| PhzA1 | pyocyanin synthesis (phenazine synthesis cluster) | PA4210 |
| PhzA2 | pyocyanin synthesis (phenazine synthesis cluster,first gene) | PA1899 |
| pvcA | pyoverdine biosynthesis protein PvcA, first of four ORF cluster | PA2254 |
| hem | putative hemagglutinins (43% identity to B. pertussis) | PA0041 |
| rnr | exoribonuclease RNase R (virulence protein VacB) class2 | PA4937 |
| adh | probable adhesion protein | PA2407 |
| znuA | probable adhesion | PA5498 |
| fliC | flagellin | PA1092 |
| flhA | flagellar biosynthesis protein | PA1452 |
| migA | probable glycosyl transferase (mucin-inducible gene) | PA0705 |
| oprH | PhoP/Q and low Mg2+ inducible outer membrane protein H1 precursor | PA1178 |
| PA4350 (pKD203) | Putative hemolysin | PA4350 |
The environmental conditions tested.
| Condition number | Condition code | Description | Condition number | Condition code | Description |
| 1 | C1T1 | M9 medium (-Tp) | 37 | C2T13 | THY medium |
| 2 | C1T2 | with PAO spent culture | 38 | C2T14 | stavation M9+0.05%gluc |
| 3 | C1T3 | BHI medium | 39 | C2T15 | co-culture with P1 isolate |
| 4 | C1T4 | LB medium | 40 | C2T16 | co-culture with E3 isolate |
| 5 | C1T5 | M9+0.05% CAA | 41 | C2T17 | with 1% PAO biofilm effluent |
| 6 | C1T6 | 1% H2O | 42 | C2T18 | with subinhibitory Gm |
| 7 | C1T7 | control 1 | 43 | C2T19 | with 10 uM AI-2 |
| 8 | C1T8 | with 2.5% methanol | 44 | C2T20 | with supernatant of PAO+gram |
| 9 | C1T9 | control 2 | 45 | C2T21 | with supernatant of PAO |
| 10 | C1T10 | M9+1% BHI | 46 | C2T22 | with supernatant of PAO |
| 11 | C1T11 | M9 with 1% AHL C4 | 47 | C2T23 | TSBDC+400 ug/ml EDDA |
| 12 | C1T12 | control 3 | 48 | C2T24 | with AI-2 |
| 13 | C1T13 | LB medium | 49 | C3T1 | co-culture with isolate N18(-Tp) |
| 14 | C1T14 | M9 with 0.5% Gluc | 50 | C3T2 | co-culture with isolate P11 |
| 15 | C1T15 | control 4 | 51 | C3T3 | 1/4 diluted LB |
| 16 | C1T16 | M9+1% Gluc | 52 | C3T4 | 1/4diluted THY |
| 17 | C1T17 | 1/4 diluted THY | 53 | C3T5 | 1/4 diluted BHI |
| 18 | C1T18 | control 5 | 54 | C3T6 | with AI-2 analog #18 |
| 19 | C1T19 | control 6 | 55 | C3T7 | co-culture with isolate N18 |
| 20 | C1T20 | 1/4 diluted THY | 56 | C3T8 | with sputum extract and tobromycin |
| 21 | C1T21 | 1/4 dilute THY | 57 | C3T9 | with subinhibitory Gm |
| 22 | C1T22 | 1/4 diluted BHI | 58 | C3T10 | M9 with 5% gluc and CAA |
| 23 | C1T23 | TSBDC medium | 59 | C3T11 | 1%(40% CAN |
| 24 | C1T24 | PBS buffer 10% | 60 | C3T12 | M9+CAA+Gluc+Tmp |
| 25 | C2T1 | co-culture with isolate D4(-Tp) | 61 | C3T13 | 1/4 diluted THY |
| 26 | C2T2 | co-culture with isolate P1 | 62 | C3T14 | 250 mM NaCI |
| 27 | C2T3 | 1/4 diluted BHI | 63 | C3T15 | co-culture with isolate P11 |
| 28 | C2T4 | THY medium | 64 | C3T16 | co-culture with isolate 9-2-8 |
| 29 | C2T5 | THY medium | 65 | C3T17 | with supernatant of PAO+CF G+ve isolate |
| 30 | C2T6 | with 25uM AI-2 | 66 | C3T18 | with Cm 2 ug/ml |
| 31 | C2T7 | co-culture with isolate D4 | 67 | C3T19 | 5 uM AI-2 diluted in water |
| 32 | C2T8 | with 1% sputum extract | 68 | C3T20 | with supernatant of PAO 50% |
| 33 | C2T9 | with subinhibitory tobramycin | 69 | C3T21 | with supernatant of PAO+CF G+ve isolate |
| 34 | C2T10 | 1% D4 supernatant | 70 | C3T22 | with supernatant of PAO |
| 35 | C2T11 | 1% AHL C4 | 71 | C3T23 | with supernatant of PAO and G+ve isolate |
| 36 | C2T12 | with 2.5% sputum extract | 72 | C3T24 | 0.25 mM Boric acid |